FDA Clears Groundbreaking Vaccine for Infant RSV Prevention via Maternal Immunization
FDA has approved Pfizer’s Abrysvo, the first vaccine for gestational immunization, safeguarding infants up to 6 months from respiratory syncytial virus (RSV) ailments. Administered during weeks 32-36 of pregnancy, Abrysvo was proven effective in…
Continue Reading